Risk assessment for metastatic testis cancer

Urologic Clinics of North America

Volumn 25, Issue 3, 1998, Pages 389-395

  McCaffrey, J A ^a   Bajorin, D F ^a   Motzer, R J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CARCINOEMBRYONIC ANTIGEN; CHORIONIC GONADOTROPIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CISPLATIN; FOLLITROPIN; LACTATE DEHYDROGENASE; LUTEINIZING HORMONE; TUMOR MARKER;

CANCER INVASION; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; GERM CELL TUMOR; HUMAN; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; SEMINOMA; TESTIS CANCER;

EID: 0031904748     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0094-0143(05)70029-X     Document Type: Article

References (32)

1. AJCC Cancer Staging Manual 1997 Lippincott-Raven Philadelphia
2. D. Bajorin A. Katz E. Chan Comparison of criteria for assigning germ cell tumor patients to “good risk” and “poor risk” studies J Clin Oncol 6 1988 786 792
3. D. Bajorin M. Mazumdar V. Vlamis Factors predictive of response to platinum-based chemotherapy in germ cell tumors: A multivariate analysis in 773 patients Proc Am Soc Clin Oncol 12 1993 234
4. D.F. Bajorin M.F. Sarosdy D.G. Pfister Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: A multiinstitutional study J Clin Oncol 11 1993 598 606
5. R. Birch S. Williams A. Cone Prognostic factors for favorable outcome in disseminated germ cell tumors J Clin Oncol 4 1986 400 407
6. G.J. Bosl N.L. Geller D.B. Bajorin A comparison of the Memorial Hospital and Einhorn classifications of germ cell tumor (GCT) patients Proc Am Soc Clin Oncol 7 1988 121
7. G.J. Bosl N.L. Geller D.B. Bajorin A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors J Clin Oncol 6 1988 1231 1238
8. G.J. Bosl N.L. Geller E.Y.W. Chan Stage migration and the increasing proportion of complete responders in patients with advanced germ cell tumors Cancer Res 48 1988 3524 3527
9. G.J. Bosl N. Geller C. Cirrincione Multivariate analysis of prognostic variables in patients with metastatic testicular cancer Cancer Res 43 1983 3403 3407
10. G.J. Bosl N.L. Geller N.J. Vogelzang Alternating cycles of etoposide plus cisplatin and VAB-6 in the treatment of poor-risk patients with germ cell tumors J Clin Oncol 5 1987 436 440
11. G.J. Bosl R. Gluckman N. Geller VAB-6: An effective chemotherapy regimen for patients with germ-cell tumors J Clin Oncol 4 1986 1493 2499
12. G.J. Bosl J. Sheinfeld D. Bajorin R. Motzer Cancer of the testis V.T.J. Devita Cancer Principles and Practice of Oncology 1997 Lippincott-Raven New York 1397 1425
13. E. Dmitrovsky D. Moy W.H. Miller Retinoic acid causes a decline in TGF-alpha expression, cloning efficiency, and tumorigenicity in a human embryonal cancer cell line Oncogene Res 5 1990 233 239
14. L. Einhorn S. Williams P. Loehrer Evaluation of optimal duration of chemotherapy in favorable- prognosis disseminated germ cell tumors: A Southeastern Cancer Study Group protocol J Clin Oncol 7 1989 387 391
15. M. Fritsche C. Haessler G. Brandner Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents Oncogene 8 1993 307 318
16. M. Hollstein D. Sidransky B. Vogelstein C. Harris p53 mutations in human cancers Science 253 1991 49 53
17. International Germ Cell Consensus classification A prognostic factor-based staging system for metastatic germ cell cancers J Clin Oncol 15 1997 594 603
18. M.B. Kastan O. Onyekwere D. Sidransky Participation of p53 protein in the cellular response to DNA damage Cancer Res 51 1991 6304 6311
19. S.W. Lowe H.E. Ruley T. Jacks D.E. Housman p53-dependent apoptosis modulates the cytotoxicity of anticancer agents Cell 74 1993 957 967
20. P.J. Mencel R.J. Motzer M. Mazumdar Advanced seminoma: Treatment results, survival, and prognostic factors in 142 patients J Clin Oncol 12 1994 120 126
21. W. Miller D. Moy A. Li Retinoic acid induces down-regulation of several growth factors and proto-oncogenes in a human embryonal cancer cell line Oncogene 5 1990 511 517
22. E.S. Newlands R.H. Begent G.J. Rustin Further advances in the management of malignant teratomas of the testis and other sites Lancet 1 1983 948 951
23. J.S. Nisselbaum G. Bosl M.K. Schwartz Argument in favor of using mass units to calibrate and report concentrations of human choriogonadotropin Clin Chem 32 1986 1998 2000
24. R.F. Ozols D.C. Ihde W.M. Linehan A randomized trial of standard chemotherapy vs a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors J Clin Oncol 6 1988 1031 1040
25. D.G. Pfister R.J. Motzer K. Cooper Treatment of poor risk nonseminotous germ cell tumor (NSGCT) patients with carboplatin (CBDCA) + etoposide (E) + bleomycin (B) Proc Am Soc Clin Oncol 8 1989 131
26. Prognostic factors in advanced nonseminomatous germ-cell testicular tumours: Results of a multicentric study. Report from the Medical Research Council Working Party on testicular tumors Lancet 1 1985 8 11
27. B.J. Roth A. Greist P.S. Kubilis Cisplatin-based combination chemotherapy for disseminated germ cell tumors: Long-term follow-up J Clin Oncol 6 1988 1239 1247
28. Ruspin GJS, Vogelzang NJ: Consensus statement on evaluating tumor markers and staging of patients with germ cell tumors. In Prostate Cancer and Testicular Cancer, EORTC Genitourinary Group Monograph 7. New York, Alan Liss, (in press)
29. G. Stoter S. Kaye D.T. Sleyfer Preliminary results of BEP (bleomycin, etoposide, cisplatin) versus an alternating regimen of BEP and PVB (cisplatin, vinblastine, bleomycin) in high volume metastatic (HVM) testicular non-seminomas. An EORTC study Proc Am Soc Clin Oncol 5 1986 106
30. G. Stoter R. Sylvester D.T. Sleijfer Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer: Results from a European Organization for Research on Treatment of Cancer Multi-institutional Phase III study Cancer Res 47 1987 2714 2718
31. N.J. Vogelzang Prognostic factors in metastatic testicular cancer Int J Androl 10 1987 225 237
32. H. Xiao D. Bajorin M. Mazumdar p53 accumulation and expression of epidermal growth factor receptor and HST-1/kFGF by immunochemistry and apoptosis by TUNEL in testicular germ cell tumors (GCT) Am Assoc Cancer Res 38 1997 424